Are biosimilars similar enough?
Why do charities need to keep funding research into leukemia and blood cancer in general?
KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Hematology-Oncology programs within the UK's hematology community
Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue